Response of lamb ductus arteriosus to @entity1242 and XXXX .

@entity1568 @entity742 @entity1242 @entity26 @entity1854 @entity2461 @entity3009 @entity5015 @entity299 @entity551 @entity4095
In certain forms of @entity299 , @entity2461 arteriosus is critical for survival. Since the administration of @entity3009 is associated with adverse side effects, this study was undertaken to evaluate the effects of @entity1242 and @entity1854 on ductal blood flow during @entity26 -induced ductal closure. Fifteen near-term fetal @entity742 were instrumented acutely. Ductal blood flow and pre- and post-ductal pressures were monitored continuously. After obtaining control data, intravenous bolus injections of @entity1242 (250 micrograms), @entity1854 (250 micrograms), or @entity5015 (5 micrograms) were administered during ventilation with either 100% @entity1568 or 100% @entity26 . All three agents significantly increased ductal blood flow during @entity1568 ventilation ( @entity4095 = 15 +/- 1 mm Hg). When the @entity742 were ventilated with 100% @entity26 , the arterial @entity4095 increased to 107 +/- 14 mm Hg, and this was associated with a marked @entity551 from 275 +/- 44 to 83 +/- 11 ml/min (P less than 0.05). When @entity1242 was administered during @entity26 -stimulated ductal closure, ductal blood flow increased 184%, from 79 +/- 18 to 225 +/- 18 ml/min (P less than 0.05); @entity1854 increased ductal blood flow 126%, from 86 +/- 20 to 195 +/- 25 ml/min (P less than 0.05); @entity5015 increased ductal blood flow 110%, from 84 +/- 18 to 178 +/- 17 ml/min (P less than 0.05). These data demonstrate that both @entity1242 and @entity1854 are potent vasodilators of the ductus arteriosus and, like @entity5015 , can markedly attenuate the @entity26 -induced ductal vasoconstriction. These results imply that @entity1242 and @entity1854 may be useful clinically in maintaining ductal patency.
